CRA developed economic analyses to determine damages in a patent infringement case involving a pharmaceutical product used for the treatment of congestive heart failure and skinny labeling by a generic competitor. CRA provided an initial report on economic damages calculating lost profits and reasonable royalties as well as deposition and trial testimony.
Trade Secret Litigation Watch: August 2025
In this Insights, CRA’s Intellectual Property Practice consultants take a closer look at trade secret case filings and developments from the first half of...